Focusing on Niche Pharmaceutical Markets: Funds Zero In on API Investment Opportunities


Release date:

2019-12-07

The latest edition of the national medical insurance catalog was recently released, sending ripples through the pharmaceutical sector. At this juncture, how should investors seize opportunities in the industry? According to reports from industry insiders, a large number of imported originator drugs have gained inclusion in the national reimbursement list by trading price for volume, intensifying competition in the domestic pharmaceutical market. Analysts note that, amid downward pricing pressures and sharply declining gross margins, cost control has become paramount, creating strategic opportunities for API‑and‑formulation manufacturers; as a result, certain API companies have recently attracted strong market interest.

The latest version of the national medical insurance catalog was recently released, sending ripples through the pharmaceutical sector. At this juncture, how should investors seize opportunities in the industry? According to reports from industry insiders, a large number of imported originator drugs have gained inclusion in the national reimbursement list by trading price for volume, intensifying competition in the domestic pharmaceutical market. Analysts note that, amid downward pricing pressures and a sharp decline in gross margins, cost control has become paramount, creating strategic opportunities for API‑and‑formulation manufacturers; consequently, several API companies have recently attracted strong market interest.

API companies are in high demand.


Since mid-November, API manufacturers such as Tonghe Pharmaceutical (300636), Aoxiang Pharmaceutical (603229), and Tianyu Shares (300702) have been highly sought after by the market. In just over two weeks, Aoxiang Pharmaceutical’s share price has risen nearly 50%, Tonghe Pharmaceutical’s has gained about 30%, while Tianyu Shares and Pulo Pharmaceutical (000739) have both hit record highs.


According to institutional research reports, over the past month, Tonghe Pharmaceutical has hosted two rounds of investor visits. On November 1, Fu Weiqi, General Manager of the Research Department at Rongtong Fund, and Huang Kairui, Investment Director at Xin Huoli Capital, conducted a site visit; on November 26, Ye Feng, an investment manager at Guotai Fund, paid a visit.


Key issues of concern to investors include the listed company’s production capacity, its upcoming product strategy, whether it plans to enter the finished‑dosage‑form sector, and its pricing power for active pharmaceutical ingredients. Tonghe Pharmaceutical disclosed that it is currently building a formulation‑manufacturing facility and will actively expand its pipeline of new products. At present, several novel candidates are under development in areas such as anticoagulants, anti‑gout agents, antidiabetic drugs, dermatological treatments, and therapies for anemia.


Notably, amid strong market interest in the API sector, some companies have seen sharp gains on the very day they host institutional investor visits. Take Tonghe Pharmaceutical as an example: following a research visit by Cathay Fund on November 26, its share price surged 25% in just four trading sessions.


Several listed companies recently announced that their active pharmaceutical ingredients (APIs) have passed technical reviews. On November 29, Sailong Pharmaceutical (002898) stated that its tigecycline API had recently received approval following a technical review by the Center for Drug Evaluation of the National Medical Products Administration. On November 11, Meinuohua (603538) issued an announcement indicating that it had obtained relevant certificates from the European Medicines Agency for rosuvastatin calcium (API). Meanwhile, Xianju Pharmaceutical (002332) disclosed on an interactive platform that some of its API products have already secured regulatory approvals and registrations in the United States, the European Union, Japan, and other markets. The company plans to continue expanding into high-end international markets and gradually increase its share of the global market for APIs compliant with international standards.

Institutions are bullish on long-term value.


From an institutional perspective, Gu Ruofei, Chairman of Panyao Asset, notes that, judging by the pharmaceutical industry’s development trajectory, the inclusion of imported originator drugs in national medical insurance has spurred domestic firms to accelerate innovation. However, whether they can withstand the pressure from global giants remains uncertain. As pharmaceutical companies transition from a nurturing environment to a fiercely competitive battlefield, effective control over API costs has become paramount.


“From the perspective of active pharmaceutical ingredients (APIs), we acknowledge a gap between domestic and imported products. However, for certain mainstream APIs, domestic quality is fully comparable to that of Europe and the United States, while the prices of imported excipients are more than twice those of their domestic counterparts. As a pharmaceutical sub‑segment that has long been overlooked, APIs stand to expand their market share by leveraging the cost‑reduction benefits of centralized procurement, thereby replicating the path of domestic substitution for imports that has already unfolded in the drug and medical device sectors,” analyzed Gu Ruofei.


Cheng Zhou, a star fund manager at Cathay Fund, believes that driven by pharmaceutical regulatory policies and industry development trends, China’s API sector is poised to enter a golden period of growth, with substantial room for expansion that could sustain itself for at least five to ten years. In Cheng Zhou’s view, both cyclical and supply‑demand dynamics, as well as policy factors, are delivering significant tailwinds to specialty APIs.


“Under the new consistency‑evaluation standards, associated approval is required. If the API manufacturer changes, a new application must be submitted, thereby enhancing the API manufacturer’s influence,” explained Cheng Zhou.


It is understood that, following the implementation of the new volume‑based procurement regulations, the pricing model for active pharmaceutical ingredients (APIs) has also shifted. Previously, API suppliers to formulation manufacturers typically set prices using a cost‑plus approach; however, as API producers have gained greater pricing autonomy, pricing has transitioned to a profit‑sharing model, giving API companies substantial room to adjust their margins.


Chen Heng, fund manager of the Huashang New Dynamic Fund, is also bullish on the API sector, particularly high-end specialty API companies. In his view, some domestic specialty API firms have already attained international competitiveness, with ample room for demand growth and steady expansion; meanwhile, supply-side constraints—stemming from environmental regulations, certification hurdles, and process‑related barriers—have led to a gradual elimination of excess capacity in recent years, improving the competitive landscape and creating investment opportunities worth watching.


Leave a Message Online

Please fill out the form, and we will get back to you as soon as possible!

Consultation Service Hotline

86-0717-6555905

Address: No. 509, East Lin Road, Bio-Industrial Park, High-tech Zone, Yichang City, Hubei Province, China

International Marketing Department

Contact: Vivian Guo

Email: Vivian.guo@tianrenpharm.com

Phone: 86-15997560212

WhatsApp: +86-15997560212


All rights reserved: Yichang Tianren Pharmaceutical Co., Ltd.

This website supports both IPv4 and IPv6 bidirectional access.

%E7%AC%AC%E4%B8%80%EF%BC%8C%E6%9C%80%EF%BC%8C%E4%BC%98%E7%A7%80%EF%BC%8C%E5%A2%9E%E5%BC%BA%EF%BC%8C%E4%B8%80%E6%B5%81%EF%BC%8C%E5%8D%93%E8%B6%8A%EF%BC%8C%E9%A2%86%E5%85%88%EF%BC%8C%E5%85%88%E8%BF%9B%EF%BC%8C%E5%BC%95%E9%A2%86%EF%BC%8C%E7%9F%A5%E5%90%8D%EF%BC%8C%E7%BA%A7

Sorry,当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry,The current column has no content!

You can view other columns or return Home